Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

E-sigaretter for skadereduksjon hos røykere med opioidbruksforstyrrelse

5. november 2026 oppdatert av: NYU Langone Health

Effektiviteten og virkningen av rådgivning forbedret med elektroniske sigaretter for skadereduksjon hos røykere med opioidbruksforstyrrelse

The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

302

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New York
      • New York, New York, Forente stater, 10016
      • The Bronx, New York, Forente stater, 10461
        • Har ikke rekruttert ennå
        • Albert Einstein College of Medicine
        • Hovedetterforsker:
          • Shadi Nahvi, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

21 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Currently smokes 5 or more CPD
  2. Age ≥ 21 years
  3. Has a diagnosis of Opioid Use Disorder
  4. In OUDTP (buprenorphine or methadone) ≥ 12 weeks via self-report or EHR records
  5. Stable methadone or buprenorphine dose for two weeks via self-report or EHR records
  6. Interested in reducing combustible cigarette (CC) smoking but not necessarily trying to quit
  7. Own a mobile phone or have regular access to a mobile phone.
  8. Able to provide an additional contact to improve follow-up rates.

Exclusion Criteria:

  1. Does not speak English or Spanish
  2. Are pregnant or breastfeeding
  3. Not able to provide consent
  4. Used tobacco products other than CC in the past 2 weeks (e.g., EC, cigarillo)
  5. Currently engaged in an attempt to quit CC smoking
  6. Reports having severe chronic obstructive pulmonary disease or asthma (i.e., with exacerbation requiring hospitalization or intubation in the prior 6 months)
  7. Reports current major depressive or manic episode, current psychotic disorder, past-year suicide attempt or psychiatric hospitalization, or current suicidal ideation with plan or intent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Electronic Cigarette

Participants in the Electronic Cigarette (EC) arm will receive telehealth motivational counseling for 5 weeks plus the standardized research e-cigarette (SREC).

At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15~20 minutes each.

Participants are to use the electronic cigarette freely as replacement for smoking combustible cigarettes.

Aktiv komparator: Nicotine Replacement Therapy

Participants in the Nicotine Replacement Therapy (NRT) arm will receive telehealth motivational counseling plus combination NRT (patch and lozenge).

At baseline, after randomization, participants will receive their first telehealth session (20~25 minutes) from a counselor trained in motivational interviewing, harm reduction, and smoking cessation. Four additional sessions will be delivered (weeks 2, 3, 4, 6), 15~20 minutes each.

Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of Participants who Achieve 100% Reduction in Cigarettes Per Day (CPD) between Baseline and End of Intervention (Visit 5)
Tidsramme: Up to Visit 5 (Day 56)

Verified by exhaled carbon-monoxide (eCO) level.

Up to Visit 5 (Day 56)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall luftveissymptomer rapportert ved baseline
Tidsramme: Grunnlinje
Grunnlinje
Antall luftveissymptomer rapportert ved avsluttet behandling (besøk 5)
Tidsramme: Besøk 5 (dag 56)
Besøk 5 (dag 56)
Antall luftveissymptomer rapportert ved måned 6 oppfølging
Tidsramme: Måned 6
Måned 6
Percentage of Participants who Achieve 100% Reduction in CPD between Baseline and Month 6 Follow-Up
Tidsramme: Month 6

Verified by exhaled carbon-monoxide (eCO) level.

Month 6
Percentage of Participants who Achieve 100% Reduction in CPD between End of Intervention (Visit 5) and Month 6 Follow-Up
Tidsramme: From Visit 5 (Day 56) up to Month 6

Verified by exhaled carbon-monoxide (eCO) level.

From Visit 5 (Day 56) up to Month 6
Change from Baseline in Self-Reported CPD at End of Intervention (Visit 5)
Tidsramme: Baseline, Visit 5 (Day 56)

Verified by exhaled carbon-monoxide (eCO) level.

Baseline, Visit 5 (Day 56)
Change from Baseline in Self-Reported CPD at Month 6
Tidsramme: Baseline, Month 6

Verified by exhaled carbon-monoxide (eCO) level.

Baseline, Month 6
Change from Baseline in Health-Related Quality of Life (HRQOL) Survey Score at End of Intervention (Visit 5)
Tidsramme: Baseline, Visit 5 (Day 56)

8-item self assessment of participants' perceived physical and mental health over time. Each item lists a condition. For each item, participants indicate the number of days the condition applied to them. The total score is the average of responses and ranges from 0-30. Lower scores indicate greater perceived physical and mental health. A reduction in scores indicates perceived physical and mental health improved over the observational period.

Baseline, Visit 5 (Day 56)
Change from Baseline in Health-Related Quality of Life (HRQOL) Survey Score at Month 6 Follow-up
Tidsramme: Baseline, Month 6

8-item self assessment of participants' perceived physical and mental health over time. Each item lists a condition. For each item, participants indicate the number of days the condition applied to them. The total score is the average of responses and ranges from 0-30. Lower scores indicate greater perceived physical and mental health. A reduction in scores indicates perceived physical and mental health improved over the observational period.

Baseline, Month 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Omar El-Shahawy, NYU Langone Health

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. august 2024

Primær fullføring (Antatt)

10. februar 2027

Studiet fullført (Antatt)

30. april 2027

Datoer for studieregistrering

Først innsendt

1. februar 2023

Først innsendt som oppfylte QC-kriteriene

9. februar 2023

Først lagt ut (Faktiske)

10. februar 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [Omar.ElShahawy@nyulangone.org]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-delingstidsramme

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Tilgangskriterier for IPD-deling

The investigator who proposed to use the data and researchers who provide a methodologically sound proposal will be granted access to the data upon reasonable request. Requests should be directed to Omar.ElShahawy@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere